Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Synopsis

Phylogenetic Analysis of Spread of Hepatitis C Virus Identified during HIV Outbreak Investigation, Unnao, India

Arati Mane, Sunitha Manjari Kasibhatla, Pallavi Vidhate, Vandana Saxena, Sandip Patil, Amrita Rao, Amit Nirmalkar, Urmila Kulkarni-Kale, and Samiran PandaComments to Author 
Author affiliations: Indian Council of Medical Research–National AIDS Research Institute, Pune, India (A. Mane, P. Vidhate, V. Saxena, S. Patil, A. Rao, A, Nirmalkar, S. Panda); Savitribai Phule Pune University Bioinformatics Centre, Pune (S.M. Kasibhatla, U. Kulkarni-Kale); Centre for Development of Advanced Computing High Performance Computing–Medical and Bioinformatics Applications Group, Pune (S.M. Kasibhatla); Indian Council of Medical Research, New Delhi, India (S. Panda)

Main Article

Table 1

Characteristics of anti-HCV positive persons identified during HIV outbreak investigation, by HIV serostatus, Unnao, India*

Characteristic HIV–HCV co-infection HCV monoinfection p value
Total no. persons
 28 (100)
 70 (100)
Mean age, y
 50
 38
 0.044
Sex
M 09 (32.1) 33 (47.1) 0.175
F
 19 (67.9)
 37 (52.9)
Area of residence
Chakmeerapur 12 (42.9) 32 (45.7) 0.957
Kirvidyapur 1 (3.6) 2 (2.9)
Premganj
 15 (53.6)
 36 (51.4)
Occupation
Unemployed 17 (60.7) 29 (41.4) 0.147
Farmer 5 (17.9) 12 (17.1)
Nonagricultural
 6 (21.4)
 29 (41.4)
Ever had sex with female casual partner (as reported by male participants)†
Yes 1 (14.3) 2 (6.1) 0.453
No
 6 (85.7)
 31 (93.9)
Ever had sex with male casual partner (as reported by female participants)†
Yes 1 (5.26) 0 0.345
No
 18 (94.74)
 36 (100)
Condom use during last sex†
Yes 3 (12.5) 11 (17.2) 0.750
No
 21 (87.5)
 53 (82.8)
Intravenous injection in therapeutic setting in past 5 years
Yes 27 (96.4) 47 (67.1) 0.002
No
 1 (3.6)
 23 (32.86)
Intramuscular injection in therapeutic setting in past 5 years
Yes 27 (96.4) 45 (64.3) 0.001
No
 1 (3.6)
 25 (35.7)
Way syringe and needle used while receiving intramuscular injection in past 5 years†
Injected by used syringe and needle 9 (32.1) 3 (4.3) 0.0001
Injected by new syringe and needle 13 (46.4) 60 (85.7)

*Values are no. (%) except as indicated. HCV, hepatitis C virus. †Because of nonresponse from some participants, numbers may not sum to total.

Main Article

Page created: February 15, 2022
Page updated: March 21, 2022
Page reviewed: March 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external